Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E26.27 EPS (ttm)3.95 Insider Own- Shs Outstand2.70B Perf Week1.92%
Market Cap280.48B Forward P/E19.09 EPS next Y5.44 Insider Trans- Shs Float415.24M Perf Month5.31%
Income9.70B PEG4.17 EPS next Q1.33 Inst Own9.90% Short Float0.65% Perf Quarter0.39%
Sales51.75B P/S5.42 EPS this Y16.20% Inst Trans0.45% Short Ratio1.73 Perf Half Y9.53%
Book/sh32.60 P/B3.18 EPS next Y5.61% ROA15.00% Target Price112.75 Perf Year22.71%
Cash/sh2.15 P/C48.29 EPS next 5Y6.30% ROE26.30% 52W Range81.85 - 106.84 Perf YTD15.14%
Dividend2.67 P/FCF78.00 EPS past 5Y3.20% ROI10.50% 52W High-2.89% Beta0.56
Dividend %2.57% Quick Ratio0.60 Sales past 5Y3.50% Gross Margin66.60% 52W Low26.75% ATR1.68
Employees120000 Current Ratio0.80 Sales Q/Q-52.20% Oper. Margin21.40% RSI (14)53.26 Volatility0.96% 1.24%
OptionableYes Debt/Eq0.30 EPS Q/Q-63.50% Profit Margin37.80% Rel Volume0.94 Prev Close103.18
ShortableYes LT Debt/Eq0.17 EarningsJul 21 BMO Payout34.00% Avg Volume1.57M Price103.75
Recom1.80 SMA201.07% SMA501.56% SMA2006.42% Volume1,469,936 Change0.55%
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Jul-31-15 09:03AM  Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog
Jul-30-15 06:51PM  Amgen hikes 2015 forecast after 2Q increase in profit, sales
11:32AM  GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
10:30AM  Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog
09:06AM  Novartiss Shares Fall after 2Q15 Earnings
08:56AM  Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers
Jul-29-15 01:30PM  GSK Boosted by New Vaccines at The Wall Street Journal
11:28AM  HIV/Aids treatments stand out as GSK promises 40-drug pipeline at Financial Times
11:06AM  Why Sandoz Revenues Were Important for Novartis in 2Q15
10:00AM  GSK earnings relief
09:06AM  Why Alcons Performance Was Weak in 2Q15
09:04AM  Eli Lilly & Co. Earnings Analysis: By the Numbers
09:04AM  GSK flags up pipeline as HIV drugs help it beat profit forecasts
08:56AM  Glaxo Earnings Beat Estimates on AIDS Drugs, Cost Reductions at Bloomberg
08:30AM  Drugmaker GSK sees earnings growth returning in 2016
08:16AM  GSK sees drop in earnings after asset swap with Novartis
07:37AM  GlaxoSmithKline second-quarter beats despite Advair hit, lower margins
07:10AM  GlaxoSmithKline Q2 beats despite Advair hit, lower margins
Jul-28-15 02:54PM  Why Pharmaceutical Eli Lilly & Co. Warrants Attention from Investors Right Now - Stocks in the News
11:46AM  Why Novartiss Revenues Declined Marginally
11:45AM  Novartiss Adjusted Earnings per Share Declined 7% in 2Q15
Jul-27-15 06:02AM  New heart drugs come in more expensive than expected Reuters
Jul-24-15 05:17PM  FDA OK's Odomzo from Novartis for common skin cancer type
02:49PM  FDA OK's Odomza from Novartis for common skin cancer type
11:12AM  AbbVie: Beware the Biosimilars? at
Jul-22-15 01:41PM  Court of Appeals Biosimilars Decision Does Not Assure Zarxio Launch in September
12:35PM  New IndexIQ ETFs Bring the Neutral to Currency Hedged ETFs
10:43AM  Novartis (NVS) Beats on Earnings in Q2, 2015 View Retained - Analyst Blog
10:10AM  Company News for July 22, 2015 - Corporate Summary
12:13AM  Novartis Can Sell Copycat of Amgens Neupogen in September, Court Rules at The Wall Street Journal
Jul-21-15 08:14PM  Appeals court says rival can sell copy of Amgen drug Neupogen at Los Angeles Times
06:40PM  Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
06:38PM  Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog
03:54PM  Court ruling clears way for Novartis' low-cost biotech drug
02:54PM  Novartis Can Sell Copycat of Amgen's Neupogen in September at The Wall Street Journal
01:37PM  Novartis (NVS) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
01:15PM  Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles at Investor's Business Daily
10:24AM  Novartis Blurs Vision of Its Potential at The Wall Street Journal
08:48AM  3 High-Dividend Pharmaceutical Stocks to Buy at TheStreet
08:19AM  Novartis CEO Says U.S. Insurance M&A to Crimp Drug Prices
08:04AM  Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more at CNBC
07:51AM  European shares fall, pulled down by drugmakers
07:44AM  Novartis earnings fall, CEO focuses on heart drug at CNBC
07:36AM  Novartis chief looks to blockbuster drugs to counter profits drop at Financial Times
06:13AM  Novartis' now offers generic MS drug: CEO
05:45AM  Novartis Profit Misses Estimates Amid Weak Lens Unit Sales
05:28AM  Weak eyecare sales trip up Novartis drug growth story
04:51AM  Novartis bullish on Afinitor cancer drug despite new competition
04:32AM  Financial Institutions in Greece Remain Closed
04:30AM  Drugmakers push European shares further away from highs
03:50AM  Novartis Profit Misses Estimates Amid Faltering Lens Unit Sales at Bloomberg
03:17AM  Novartis (NVS) Beats on Earnings & Revenues in Q2 - Tale of the Tape
03:06AM  Strong dollar hits Novartis; reports profit miss at CNBC
02:06AM  Novartis Profit Drops as U.S. Dollar Strength Erodes Sales
01:45AM  Looking at bolt-on acquisitions: Novartis CEO
01:08AM  Novartis Profit Declines as Strength of U.S. Dollar Erodes Sales at Bloomberg
Jul-20-15 10:50AM  Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer at Investor's Business Daily
Jul-18-15 08:02AM  6 Big-Cap Drugmakers Reporting Earnings Next Week at Investor's Business Daily
Jul-17-15 01:55PM  Will Novartis (NVS) Disappoint Q2 Earnings due to Generics? - Analyst Blog
Jul-16-15 04:18PM  Chiasma Inc (CHMA)s Shares Jump 35% On First Day Of Trading at Insider Monkey
12:40PM  Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog
Jul-15-15 09:48AM  Greece Is On The Verge Of A Health Catastrophe at Forbes
Jul-14-15 01:14PM  Greece bans export of 25 drugs after pharmacists' supply warnings Reuters
Jul-12-15 11:02AM  $1.5 Trillion Reasons to Invest in These Companies at Motley Fool
Jul-10-15 05:58AM  Novartis Looking at Ways of Attracting Health Insurers at The Wall Street Journal
Jul-09-15 04:04PM  This Week's Top Healthcare News Could Cause These Stocks Pop or Drop at Motley Fool
02:57PM  Novartis Meets Skepticism in Plan to Link Drug Pay to Outcomes at Bloomberg
06:26AM  Novartis senses a blockbuster after FDA approves its new heart drug at Fortune
Jul-08-15 04:12PM  Meet the Next Mega Blockbuster Heart Drug at 24/7 Wall St.
02:00PM  Gene therapy for deafness moves a few steps closer
12:50PM  Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog
09:43AM  Novartis (NVS) Stock Climbs, FDA Approves Heart Failure Drug at TheStreet
09:25AM  New Heart Drug From Novartis Gets FDA Approval -- Now The Major Pricing Battle Begins at Forbes
06:05AM  European stocks bounce back as Barclays and Novartis rise
06:00AM  Novartis news goes straight to the heart
12:28AM  FDA Approves Novartiss Heart Failure Drug at The Wall Street Journal
Jul-07-15 07:30PM  Novartis Heart Failure Drug Approved by FDA at The Wall Street Journal
06:09PM  Novartis wins early U.S. approval for major new heart drug Reuters
05:53PM  FDA approves new heart failure pill from Novartis
05:47PM  Novartis Wins U.S. FDA Approval for Heart-Failure Treatment
Jul-02-15 03:30PM  Biogen: Where Did That Come From? at
12:11PM  Momenta Downgraded After Stock Price Doubles at Investor's Business Daily
Jul-01-15 03:24AM  U.S. Seeks $3.3 Billion From Novartis in Drug Kickback Suit at Bloomberg
Jun-30-15 11:16PM  US seeks $3.3 bn corruption fine from Novartis AFP
03:46PM  Novartis (NVS) Stock Declines as U.S. Seeks $3.35 Billion Fine at TheStreet
02:37PM  How Much?! Feds Wants Novartis to pay $3.35B For Kickback Schemes at The Wall Street Journal
11:10AM  U.S. seeks up to $3.35 billion in Novartis kickback lawsuit Reuters
10:42AM  Roche 'High Efficacy' MS Drug Succeeds In Trials at Investor's Business Daily
09:19AM  Sony slides on share plan; Apple launches music service; Juno soars on Celgene deal
Jun-29-15 04:45PM  Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog
07:52AM  Early movers: NBG, JPM, M, GCI, TWTR & more at CNBC
06:45AM  Novartis to Pay at Least $200 Million for Chronic Pain Medicine at Bloomberg
04:04AM  Switzerland's Novartis buys US biotech firm Spinifex
02:51AM  Novartis buys Spinifex for $US200m plus AAP
02:35AM  Novartis buys pain drug firm Spinifex for $200 mln upfront
Jun-28-15 07:01PM  New data fuel hopes for broad use of Novartis psoriasis drug Reuters
Jun-26-15 06:02PM  Dow 30 Stock Roundup: Nike Beats Estimates, Verizon Closes AOL Buy - Analyst Blog
11:16AM  External Innovation: Force Multiplier For R&D at Forbes
07:13AM  Europe gives green light to new Novartis, Alexion drugs Reuters
Jun-24-15 11:22AM  Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham Business Wire
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM